AbCellera and Novartis enter into multi-target partnership
Canada-based AbCellera has announced it has signed a multi-year, multi-target agreement with Novartis...
Focus:
-
![Taiho Pharmaceutical licences lung cancer drug to Cullinan Oncology]()
Taiho Pharmaceutical licences lung cancer drug to Cullinan Oncology
-
![GSK signs $4.2bn deal with Merck for M7824 immunotherapy]()
GSK signs $4.2bn immunotherapy deal with the Merck group
-
![Tesaro acquisition]()
GSK closes $5.1bn Tesaro acquisition
-
![BMS Celgene deal]()
BMS/Celgene deal will create haematology powerhouse
-
![US childhood vaccines]()
Vaxelis approval boosts Merck and Sanofi’s foothold in US childhood vaccines
-
![CANbridge, WuXi Biologics expand alliance]()
CANbridge Pharmaceuticals expands partnership with Wuxi Biologics
Most Read
Latest Content
AbCellera and Novartis enter into multi-target partnership
Canada-based AbCellera has announced it has signed a multi-year, multi-target agreement with Novartis under which its antibody discovery technology will be leveraged by the Swiss pharma giant for up to ten clinically-relevant disease targets.
Neurogene raises funds to support gene therapy development
Neurogene has secured funding during a Series A financing round to advance the development of its gene therapy candidates intended for the treatment of various neurological diseases.
Evotec and Galapagos collaborate for new fibrosis target
German biotechnology company Evotec has entered into a collaboration agreement with Belgo-Dutch pharmaceutical firm Galapagos for a new, undisclosed target to treat fibrosis.
Taiho Pharmaceutical licences lung cancer drug to Cullinan Oncology
Japan-based Taiho Pharmaceutical has signed an agreement to licence its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor candidate TAS6417 for lung cancer to Cullinan Oncology.
GSK signs $4.2bn immunotherapy deal with the Merck group
GlaxoSmithKline (GSK) has entered into a global strategic collaboration with the Merck group for an immunotherapy candidate M7824 (bintrafusp alfa) in difficult-to-treat cancers.
FSD Pharma forms new alliance for pharma-grade cannabinoids
Canada-based FSD Pharma has signed a non-binding letter of intent (LOI) with algae technology company Solarvest BioEnergy for the development of pharma-grade cannabinoids from algae.
Argenx to leverage Halozyme’s subcutaneous drug delivery technology
Dutch biotechnology company argenx has signed a global collaboration and licence agreement to leverage US-based Halozyme Therapeutics’ drug delivery technology ENHANZE.
Indivior to sell rights of opioid dependence drug in China
Specialty pharmaceutical company Indivior has agreed to sell its rights to Sai Bo Song (buprenorphine, naloxone) tablet in China to Zhejiang Pukang Biotechnology for up to $122.5m.
Janssen signs inherited retinal disease therapies deal with MeiraGTx
Johnson and Johnson subsidiary Janssen has entered into a collaboration and licence agreement with gene therapy company MeiraGTx for the development, manufacture and commercialisation of therapies to treat inherited retinal diseases.
Voyager signs $1.8bn drug development deal with Neurocrine
Voyager Therapeutics has entered a strategic alliance with Neurocrine Biosciences to develop and commercialise its gene therapy candidates intended for severe neurological conditions.
Latest News
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.
Go Top
